Showing 3801-3810 of 5646 results for "".
- Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512 for Dry Eye Diseasehttps://modernod.com/news/alcon-announces-positive-topline-results-from-phase-3-comet-trials-of-ar-15512-a-novel-topical-drug-candidate-for-dry-eye/2482063/Alcon announced positive topline results from the two pivotal phase 3 clinical trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512, a candidate treatment for the signs and symptoms of dry eye disease (DED). In both COMET-2 and COMET-3, which enrolled more than 93
- Zenni Optical Announces 2023 Eye Care Access Scholarship Winnershttps://modernod.com/news/zenni-optical-announces-2023-eye-care-access-scholarship-winners/2482062/Zenni Optical has awarded five optometry students with its 2023 Eye Care Access Scholarship. Now in its second year, the Zenni Eye Care Access Scholarship recognizes incoming students who want to provide eye care to communities in need everywhere.
- Aviceda Announces Topline Data From Part 1 of the Phase 2/3 SIGLEC Trial of GA Drug Candidate AVD-104https://modernod.com/news/aviceda-therapeutics-announces-topline-data-from-part-1-of-the-phase-23-siglec-clinical-trial-for-avd-104-demonstrating-positive-safety-and-early-clinical-efficacy-in-patients-with-geographic-atrophy/2482061/Aviceda Therapeutics announced positive topline data of part 1 of the phase 2/3 SIGLEC trial for AVD-104 in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), showing positive safety and efficacy outcomes which were observed at 3 months after a single
- Amring Pharmaceuticals Names Jai G. Parekh, MD, Chief Commercial Officer, Eye Care, UShttps://modernod.com/news/amring-pharmaceuticals-names-jai-g-parekh-md-chief-commercial-officer-eye-care-us/2482059/Amring Pharmaceuticals, a subsidiary of Nordic Group BV, has named Jai G. Parekh, MD, MBA, as Chief Commercial Officer, Eye Care, US. Nordic Pharma recently expanded its pharmaceutical presence in the US by acquiring Visant Medical, maker of the FDA-c
- Nidek Launches Mirante Scanning Laser Ophthalmoscope in the United Stateshttps://modernod.com/news/nidek-launches-mirante-scanning-laser-ophthalmoscope-in-the-united-states/2482052/Nidek announced the commercial launch of the Mirante Scanning Laser Ophthalmoscope (SLO) in the United States. The Mirante is a multimodal fundus-imaging platform that combines high-definition SLO and optical coherence tomography (OCT) with ultra-wide field imaging. The multimodal platf
- EyePoint Begins Phase 2 VERONA Clinical Trial of EYP-1901 to Treat Diabetic Macular Edemahttps://modernod.com/news/eyepoint-begins-phase-2-verona-clinical-trial-of-eyp-1901-to-treat-diabetic-macular-edema/2482049/EyePoint Pharmaceuticals, a company focused on therapeutics for retinal diseases, announced that the first patient has been dosed in the VERONA clinical trial of the company’s EYP-1901 for diabetic macular edema (DME). EYP-1901 is an investigational sustained delivery therapy containing vor
- EssilorLuxottica Showcases Nuance Audio Smart Eyewear With Hearing-Aid Solutionhttps://modernod.com/news/essilorluxottica-showcases-nuance-audio-smart-eyewear-with-hearing-aid-solution/2482051/EssilorLuxottica announced it will showcase its consumer technology at CES 2024, the Consumer Electronics Show held by the Consumer Technology Association on January 9-12 in Las Vegas, Nevada. The company is a France-based designer, manufacturer, and global distributor of eyecare and eyewear prod
- Gentex Acquires eSighthttps://modernod.com/news/gentex-acquires-esight/2482048/Gentex announced the asset acquisition of eSight, a provider of vision enhancement technologies, to develop and manufacture next-generation mobile electronic eyewear that is designed to help people living with visual impairments. The company will feature eSight’s technology at CES 2024, the
- Eylea 8 mg Approved in EUhttps://modernod.com/news/eylea-8-mg-approved-in-eu/2482046/The European Commission has granted marketing authorization in the European Union (EU) for new Eylea 8 mg (aflibercept 8 mg, 114.3 mg/ml solution for injection) for the treatment of wet age-related macular degeneration (AMD) and visual impairment due to diabetic macular edema (DME).
- Alimera Completes Recruitment for the Synchronicity Study Evaluating Yutiqhttps://modernod.com/news/alimera-completes-recruitment-for-the-synchronicity-study-evaluating-yutiq/2482044/Alimera Sciences announced that it has completed enrollment for the company’s Synchronicity study, a prospective, open-label clinical study evaluating the safety and efficacy of Yutiq (fluocinolone acetonide intravitreal implant 0.18mg) in the treatment of chronic noninfectious uveitis